Tumor Biology

, Volume 36, Issue 11, pp 8773–8780 | Cite as

Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients’ outcome

  • Miodrag Dragoj
  • Zorica Milosevic
  • Jasna Bankovic
  • Jelena Dinic
  • Milica Pesic
  • Nikola Tanic
  • Tijana Stankovic
Research Article

Abstract

Cyclin D1 is one of the major cellular oncogenes, overexpressed in number of human cancers, including non-small cell lung carcinoma (NSCLC). However, it does not exert tumorigenic activity by itself, but rather cooperates with other altered oncogenes and tumor suppressors. Therefore, in the present study, we have examined mutual role of cyclin D1, KRAS, and PTEN alterations in the pathogenesis of NSCLC and their potential to serve as multiple molecular markers for this disease. CCND1 gene amplification and gene expression were analyzed in relation to mutational status of KRAS gene as well as to PTEN alterations (loss of heterozygosity and promoter hypermethylation) in NSCLC patient samples. Moreover, the effect of these co-alterations on patient survival was examined. Amplified CCND1 gene was exclusively associated with increased gene expression. Statistical analyses also revealed significant association between CCND1 overexpression and KRAS mutations in the whole group and in the groups of patients with adenocarcinoma, grade 1/2, and stage I/II. In addition, CCND1 overexpression was significantly related to PTEN promoter hypermethylation in the whole group and in the group of patients with squamous cell carcinoma and lymph node invasion. These joint alterations also significantly shortened patients’ survival and were shown to be an independent factor for adverse prognosis. Overall results point that cyclin D1 expression cooperates with KRAS and PTEN alterations in pathogenesis of NSCLC, and they could serve as potential multiple molecular markers for specific subgroups of NSCLC patients as well as prognostic markers for this type of cancer.

Keywords

CCND1 KRAS PTEN Non-small cell lung carcinoma 

Notes

Acknowledgements

This study was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (grant No III41031).

Conflicts of interest

None

References

  1. 1.
    Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003;36(1):60–5.PubMedGoogle Scholar
  2. 2.
    Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630–41. doi: 10.1016/j.tibs.2005.09.005.CrossRefPubMedGoogle Scholar
  3. 3.
    Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol. 1997;17(7):3850–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A. 1998;95(3):1091–6.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Koziczak M, Hynes NE. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem. 2004;279(48):50004–11. doi: 10.1074/jbc.M404252200.CrossRefPubMedGoogle Scholar
  6. 6.
    Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 1998;273(45):29864–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12(22):3499–511.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet. 2006;15(17):2553–9. doi: 10.1093/hmg/ddl177.CrossRefPubMedGoogle Scholar
  9. 9.
    Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84(8):2726–32.PubMedGoogle Scholar
  10. 10.
    Kramer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, et al. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia. 2002;16(9):1844–51. doi: 10.1038/sj.leu.2402609.CrossRefPubMedGoogle Scholar
  11. 11.
    Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55(1):1–14. doi: 10.1016/j.lungcan.2006.09.024.CrossRefPubMedGoogle Scholar
  12. 12.
    Hanken H, Grobe A, Cachovan G, Smeets R, Simon R, Sauter G, et al. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Invest. 2014;18(1):269–76. doi: 10.1007/s00784-013-0967-6.CrossRefGoogle Scholar
  13. 13.
    Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(2):111–9. doi: 10.1007/s00432-004-0610-7.CrossRefPubMedGoogle Scholar
  14. 14.
    Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Modern Pathol : Off J US Can Acad Pathol, Inc. 2014;27(1):87–95. doi: 10.1038/modpathol.2013.125.CrossRefGoogle Scholar
  15. 15.
    Tanic N, Milinkovic V, Dramicanin T, Nedeljkovic M, Stankovic T, Milovanovic Z et al. Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients. J Med Biochem. 2013;32(4). doi:  10.2478/jomb-2014-0005.
  16. 16.
    Andjelkovic T, Bankovic J, Stojsic J, Milinkovic V, Podolski-Renic A, Ruzdijic S, et al. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res. 2011;157(1):19–28. doi: 10.1016/j.trsl.2010.09.004.CrossRefPubMedGoogle Scholar
  17. 17.
    Sambrook J. Purification of Nucleic Acids. In: Nolan C, editor. Molecular cloning: a laboratory manual. secondth ed. Cold Spring Harbour: Cold Spring Harbor: Laboratory Press; 1989. p. E.3–4.Google Scholar
  18. 18.
    Milinkovic V, Bankovic J, Rakic M, Stankovic T, Skender-Gazibara M, Ruzdijic S, et al. Identification of novel genetic alterations in samples of malignant glioma patients. PLoS One. 2013;8(12):e82108. doi: 10.1371/journal.pone.0082108.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Schneeberger C, Eder S, Swoboda H, Ullrich R, Zeillinger R. A differential PCR system for the determination of CCND1 (cyclin D1) gene amplification in head and neck squamous cell carcinomas. Oral Oncol. 1998;34(4):257–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Wong H, Anderson WD, Cheng T, Riabowol KT. Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method. Anal Biochem. 1994;223(2):251–8. doi: 10.1006/abio.1994.1581.CrossRefPubMedGoogle Scholar
  21. 21.
    NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, Daly C, et al. Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer J Int du Cancer. 1999;82(3):368–76.CrossRefGoogle Scholar
  22. 22.
    Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, et al. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 2014;164(5):411–23. doi: 10.1016/j.trsl.2014.06.005.CrossRefPubMedGoogle Scholar
  23. 23.
    COSMIC: Catalogue of Somatic Mutations in Cancer, http://cancer.sanger.ac.uk/cosmic
  24. 24.
    Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer J Int du Cancer. 1998;75(2):187–92.CrossRefGoogle Scholar
  25. 25.
    Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group J Cancer Res Clin Oncol. 1999;125(2):61–70.CrossRefGoogle Scholar
  26. 26.
    Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220(2):292–6. doi: 10.1002/jcp.21791.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wong NA, Morris RG, McCondochie A, Bader S, Jodrell DI, Harrison DJ. Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. J Pathol. 2002;197(1):128–35. doi: 10.1002/path.1113.CrossRefPubMedGoogle Scholar
  28. 28.
    Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Marcos R, Hardisson D, Cigudosa JC, et al. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. Int J Cancer J Int du Cancer. 2004;110(2):194–200. doi: 10.1002/ijc.20130.CrossRefGoogle Scholar
  29. 29.
    Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F, et al. Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer J Int du Cancer. 1998;76(6):806–11.CrossRefGoogle Scholar
  30. 30.
    Yamazaki K, Hanami K, Nagao T, Asoh A, Sugano I, Ishida Y. Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation. Mole Pathol : MP. 2003;56(6):336–41.CrossRefGoogle Scholar
  31. 31.
    Park YH, Kim SU, Lee BK, Kim HS, Song IS, Shin HJ, et al. Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway. Antioxidants Redox Signaling. 2013;19(5):482–96. doi: 10.1089/ars.2011.4421.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Chu M, Guo J, Chen CY. Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. J Biol Chem. 2005;280(8):6369–79. doi: 10.1074/jbc.M408947200.CrossRefPubMedGoogle Scholar
  33. 33.
    Floyd HS, Jennings-Gee JE, Kock ND, Miller MS. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog. 2006;45(7):506–17. doi: 10.1002/mc.20181.CrossRefPubMedGoogle Scholar
  34. 34.
    Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. New England J Med. 1987;317(15):929–35. doi: 10.1056/NEJM198710083171504.CrossRefGoogle Scholar
  35. 35.
    Sartori G, Cavazza A, Bertolini F, Longo L, Marchioni A, Costantini M, et al. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. Am J Clin Pathol. 2008;129(2):202–10. doi: 10.1309/THU13F3JRJVWLM30.CrossRefPubMedGoogle Scholar
  36. 36.
    Weng LP, Brown JL, Eng C. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet. 2001;10(6):599–604.CrossRefPubMedGoogle Scholar
  37. 37.
    Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003;23(17):6139–49.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005;65(18):8096–100. doi: 10.1158/0008-5472.CAN-05-1888.CrossRefPubMedGoogle Scholar
  39. 39.
    Li J, Yin LL, Su KL, Zhang GF, Wang J. Concomitant depletion of PTEN and p27 and overexpression of cyclin D1 may predict a worse prognosis for patients with post-operative stage II and III colorectal cancer. Oncol Lett. 2014;8(4):1543–50. doi: 10.3892/ol.2014.2350.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Capodanno A, Camerini A, Orlandini C, Baldini E, Resta ML, Bevilacqua G, et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol. 2009;40(10):1408–17. doi: 10.1016/j.humpath.2009.02.005.CrossRefPubMedGoogle Scholar
  41. 41.
    Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Modern Pathol: Off J US Can Acad Pathol, Inc. 2006;19(2):238–45. doi: 10.1038/modpathol.3800525.CrossRefGoogle Scholar
  42. 42.
    Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001;158(6):2097–106. doi: 10.1016/S0002-9440(10)64681-0.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Engin H, Baltali E, Guler N, Guler G, Tekuzman G, Uner A. Expression of PTEN, cyclin D1, P27/KIP1 in invasive ductal carcinomas of the breast and correlation with clinicopathological parameters. Bull Cancer. 2006;93(2):E21–6.PubMedGoogle Scholar
  44. 44.
    Zhang LQ, Jiang F, Xu L, Wang J, Bai JL, Yin R, et al. The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer. 2012;13(3):188–95. doi: 10.1016/j.cllc.2011.10.003.CrossRefPubMedGoogle Scholar
  45. 45.
    Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005;36(7):768–76. doi: 10.1016/j.humpath.2005.05.006.CrossRefPubMedGoogle Scholar
  46. 46.
    Kim DS, Lee SM, Yoon GS, Choi JE, Park JY. Infrequent hypermethylation of the PTEN gene in Korean non-small-cell lung cancers. Cancer Sci. 2010;101(2):568–72. doi: 10.1111/j.1349-7006.2009.01406.x.CrossRefPubMedGoogle Scholar
  47. 47.
    Sasaki H, Okuda K, Endo K, Kawano O, Yukiue H, Yokoyama T, et al. CCND1 messenger RNA expression is correlated with EGFR mutation status in lung cancer. Clin Lung Cancer. 2007;8(8):493–6. doi: 10.3816/CLC.2007.n.034.CrossRefPubMedGoogle Scholar
  48. 48.
    Sun W, Song L, Ai T, Zhang Y, Gao Y, Cui J. Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J Biomed Res. 2013;27(3):220–30. doi: 10.7555/jbr.27.20130004.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Miodrag Dragoj
    • 1
  • Zorica Milosevic
    • 1
  • Jasna Bankovic
    • 1
  • Jelena Dinic
    • 1
  • Milica Pesic
    • 1
  • Nikola Tanic
    • 1
  • Tijana Stankovic
    • 1
  1. 1.Department of NeurobiologyUniversity of Belgrade, Institute for Biological ResearchBelgradeSerbia

Personalised recommendations